Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Melanoma 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Hematologic Neoplasms 1Cytopenia 1Coronavirus Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1

Interventions

Standard of Care 8Surveys and Questionnaires 7COVID-19 Vaccines 6Blood Specimen Collection 6BNT162 Vaccine 6Specimen Handling 52019-nCoV Vaccine mRNA-1273 5Hydroxychloroquine 4Surgical Procedures, Operative 3Practice Guidelines as Topic 3tocilizumab 2sotrovimab 2sinovac COVID-19 vaccine 2cilgavimab and tixagevimab drug combination 2Sodium Chloride 2Pandemic Preparedness 2Data Collection 2CVnCoV COVID-19 vaccine 2COH04S1 COVID-19 vaccine 2Azithromycin 2selinexor 1remdesivir 1regorafenib 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × HuMax-IL8 × Clear all
NCT04347226 2025-05-22

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Columbia University

Phase 2 Terminated
43 enrolled 14 charts
Other hematologic neoplasm

COVID-19, Coronavirus Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡